Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study

July 2025 in “ Dermatology and Therapy ”

Daniel Muñoz‐Barba, Alberto Soto‐Moreno, Saionara Cristina Francisco, Manuel Sánchez‐Díaz, Salvador Arias-Santiago

baricitinib alopecia areata therapeutic burden systemic treatments

TLDR Patients with fewer past treatments for alopecia areata respond better to baricitinib.

This study introduces the concept of Alopecia Areata-adapted Therapeutic Burden (AA-adapted TB) as a tool for categorizing patients and aiding in treatment decisions. It was found that patients with alopecia areata who had a low therapeutic burden, meaning they had undergone fewer systemic treatments previously, responded better to baricitinib treatment compared to those with a higher therapeutic burden. This suggests that the AA-adapted TB can be an effective predictor of response to baricitinib in real-life settings.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

12 / 12 results

research Real-Life Effectiveness and Safety of Baricitinib in Adults with Alopecia Areata: A Multicenter Study

March 2025 in “Journal of the European Academy of Dermatology and Venereology”

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center

research Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center

January 2025 in “The Journal of Dermatology”

Certain patient traits can predict better hair regrowth with baricitinib in severe alopecia areata.

research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata

4 citations , January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

research Treatments for Alopecia Areata: A Network Meta-Analysis

October 2023 in “The Cochrane library”

The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.

Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series

research Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series

July 2023 in “Clinical and Experimental Dermatology”

Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.

research Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis

7 citations , April 2023 in “Frontiers in immunology”

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs

1 citations , March 2023 in “Clinical, Cosmetic and Investigational Dermatology”

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations , March 2023 in “American Journal of Clinical Dermatology”

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis

10 citations , January 2023 in “Acta dermato-venereologica”

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata

40 citations , August 2022 in “Frontiers in immunology”

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

research Epidemiology and Burden of Alopecia Areata: A Systematic Review

144 citations , July 2015 in “Clinical, Cosmetic and Investigational Dermatology”

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

research The Pattern and Profile of Alopecia Areata in Singapore: A Study of 219 Asians

275 citations , November 2002 in “International Journal of Dermatology”

Alopecia areata mainly affects young people and has significant psychological impacts, especially in males.

Related Community Posts Join

6 / 14 results

Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

community Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

in Research 865 upvotes 1 year ago

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

in Research/Science 2 years ago

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

community Lilly to seek first approval of an autoimmune drug for hair loss

in Research/Science 19 upvotes 4 years ago

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?

in Treatment 7 upvotes 2 years ago

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

community I am a dermatologist with a clinical interest in alopecia. AMA

in Will treatment work for me? 3 years ago

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

community Olumiant active ingredient Baricitinib

in Research/Science 1 upvotes 3 years ago

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

Related Research

1 / 1 results

research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child

April 2019 in “International journal of research in dermatology”

A child with rough nails also had hair loss and allergies.